Bruno Paiva
PhD
Scientific Director
👥Biography 个人简介
Bruno Paiva at Navarra has been the leading authority on minimal residual disease (MRD) assessment in multiple myeloma, developing and validating next-generation flow cytometry methods for ultra-sensitive MRD detection at 1 in 100,000 cells. His work establishing MRD negativity as a surrogate endpoint for survival in myeloma clinical trials has been foundational for the International Myeloma Working Group MRD consensus criteria now used globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Bruno Paiva 的研究动态
Follow Bruno Paiva's research updates
留下邮箱，当我们发布与 Bruno Paiva（Clinica Universidad de Navarra）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment